India is emerging as a major player in the pharmaceutical industry, particularly in developing cancer drugs. With rising cancer cases, India is expected to become the cancer capital in the coming years. This growth creates immense opportunities for pharmaceutical companies specializing in oncology treatments. Some of the top manufacturers in this sector are driving advancements in chemotherapy, immunotherapy, and targeted therapies. These trends make cancer-focused pharma stocks a compelling investment opportunity in India.
1. Beta Drugs
Beta Drugs is a leading manufacturer of oncology drugs and part of the Adley Group. The company has cutting-edge research facilities. Its manufacturing plants are in Solan, Himachal Pradesh, and Derabassi, Punjab. Beta Drugs exports its products to over 35 countries.
Share Price
Beta Drugs Ltd share price: Shares of pharma company Beta Drugs Ltd are trading at Rs.2,079, 4.5% higher from its previous close of Rs. 1,981 at 11:10 am on Tuesday, November 05, 2024.
Future Outlook
Beta Drugs plans to broaden its product portfolio as it is planning to launch 25 new products by 2026. Beta Drugs is also focusing on enhancing its sales to 450+ crores by 2026. Besides this, the company strategically focuses on domestic and international markets, with a robust pipeline of over 350 registrations in development. The company is also targeting to expand its presence in Southeast Asia, Latin America, and the Middle East.
2. Shilpa Medicare
Shilpa Medicare is one of India’s largest Active Pharmaceutical Ingredient (API) manufacturers, particularly in oncology. The company operates 2 WHO-GMP-approved manufacturing plants in Karnataka and Telangana, known for their quick production capabilities and high-quality output. The company exports over 70 products including APIs to all the world’s major regions. With a primary focus on complex formulations and innovative cancer treatments.
Share Price
Shilpa Medicare Ltd share price: Shares of pharma company Shilpa Medicare Ltd are trading at Rs.827, 0.96% higher from its previous close of Rs. 819 at 11:20 am on Tuesday, November 05, 2024.
Future Outlook
Shilpa Medicare intends to make significant R&D investments to launch sophisticated oncology formulations and novel biosimilars. Shilpa Medicare has a bright future ahead of it as it prepares for substantial expansion in the formulations and Active Pharmaceutical Ingredient (API) sectors.
The company is establishing itself as a major player in the pharmaceutical market with 244 Drug Master File (DMF) filings across major international regulatory bodies. Its extensive regulatory filings, which include 74 in the EU and 501 for the Rest of the World (ROW) markets, demonstrate a strong commitment to growth as of yearly updates
Also read…
3. Venus Remedies Ltd
Venus Remedies is a specialized pharmaceutical company focusing on oncology and anti-infective drugs. The company operates WHO-GMP-certified manufacturing plants and has a presence in close to 50 countries. Venus Remedies’ expertise in producing life-saving cancer drugs like Gemcitabine and Paclitaxel positions it as a trusted name in oncology.
Share Price
Venus Remedies Ltd share price: Shares of pharma company Venus Remedies Ltd are trading at Rs.311, 0.35% higher from its previous close of Rs. 310 at 11:32 am on Tuesday, November 05, 2024.
Future Outlook
The company is focusing on developing innovative antimicrobial therapies and expanding its global presence to 100 countries. It plans to achieve a turnover of ₹1000 crores while building brand equity among healthcare providers and consumers. Additionally, Venus Remedies is planning to invest in technology to prepare its workforce for the fourth industrial revolution.
Conclusion
The Indian pharmaceutical sector shows promising growth in cancer drug manufacturing, with Beta Drugs, Shilpa Medicare, and Venus Remedies leading the charge. Their robust manufacturing capabilities, international presence, and ambitious expansion plans position them well in the global oncology market. As India faces rising cancer cases, these companies offer strong investment potential through their innovative treatments and strategic growth initiatives.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
